In kidney transplantation, ischemia-reperfusion injury (IRI) releases danger signals that activate innate immunity, and the chemokine CXCL13 rises systemically in an ischemia-duration- and alloantigen-dependent manner, accompanied by recruitment of CXCR5+ B cells into the graft. Whether this axis is a cause of graft-directed humoral alloimmunity (de novo donor-specific antibodies and antibody-mediated rejection) or merely a correlative marker of sterile injury, and which innate pathways — complement C5a/C5aR1, Toll-like receptors 2/4, cytokines such as IL-10 and IL-17 — and which cellular sources induce CXCL13 after renal IRI, remains unresolved. The problem is to settle this causal chain by loss-of-function and cell-source identification, thereby defining one concrete instance of how innate recognition of the graft initiates alloantigen-specific adaptive rejection.

Background

Kidney transplantation inevitably imposes a period without blood supply (ischemia) followed by restoration of flow (reperfusion). This ischemia-reperfusion injury (IRI) kills graft cells, which release damage-associated molecular patterns (DAMPs) — intracellular molecules such as high-mobility group proteins, extracellular ATP, and oxidized lipids that, once released, act as alarm signals. DAMPs activate recipient innate immunity through germline-encoded receptors, notably Toll-like receptors 2 and 4 (TLR2/4, membrane proteins that recognize microbial and endogenous danger ligands) and the complement system (a cascade of serum and cell-surface proteins whose activation fragments opsonize debris and recruit immune cells; the fragment C5a signals through the receptor C5aR1 on myeloid cells). The consequences of IRI include delayed graft function (DGF, the need for dialysis in the first week after transplantation) and, it is widely suspected, a heightened risk of rejection. How this antigen-independent injury feeds into alloantigen-specific adaptive immunity — the 'innate-to-adaptive handoff' — is a long-standing framing problem of transplant immunology: reviews from 2019 through 2026 consistently state that the innate mechanisms sensing allotransplants and the decisive innate receptors governing rejection remain incompletely defined (Ochando et al. 2019; Praska et al. 2023; Dery et al. 2023; Troise et al. 2025; Toyama and Thomson 2026). One concrete entry point into this handoff is the chemokine CXCL13 (also called B lymphocyte chemoattractant), a small secreted protein that binds the receptor CXCR5 and directs B cells and T follicular helper cells (Tfh, the CD4+ T-cell subset that helps B cells in germinal centers — the microanatomical sites of antibody affinity maturation in lymphoid tissue). CXCL13 is required for germinal-center organization, and elevated CXCL13 has been repeatedly associated with acute rejection, urinary CXCL13 with antibody-mediated rejection, and serum CXCL13 with T-cell-mediated rejection. Kreimann et al. (2020) established in mice that renal IRI alone rapidly raises systemic CXCL13 in proportion to ischemia duration, that ischemic kidneys upregulate CXCL13 and accumulate CD22+ B cells and CXCR5+ cells within seven days, and that after kidney transplantation serum CXCL13 scales with cold-ischemia time and is higher in allogeneic than in isogeneic (genetically identical, non-alloantigenic) grafts — indicating that both injury and alloantigen contribute. Crucially, that study was correlational by the authors' own statement: the cellular source of CXCL13 was not identified (candidates include infiltrating macrophages acting downstream of complement C5a/C5aR1, stromal cells responding to IL-17, TLR2/IL-10-dependent myeloid routes, and damaged tubular epithelial cells), and no blockade or genetic experiment tested whether CXCL13 actually recruits the CXCR5+ cells or whether recruitment instead reflects inflammation independent of CXCL13. Subsequent work strengthened only the biomarker side of the story: Crichton et al. (2021) showed in murine skin grafts and human kidney recipients that serum CXCL13 tracks germinal-center activity and precedes or accompanies de novo donor-specific antibodies (DSA — antibodies directed at donor human leukocyte antigens, the hallmark precipitant of antibody-mediated rejection, AMR). Whether the CXCL13/CXCR5 axis is required for that humoral alloresponse — and which upstream innate pathway licenses CXCL13 production after graft ischemia — has still not been tested with loss-of-function experiments in any transplantation or renal-IRI model, and a 2026 hypothesis paper (Vázquez-Toledo et al.) proposes exactly this causal role, underscoring its unresolved status.

Problem Statement

In kidney transplantation, determine whether ischemia-reperfusion injury and the danger signaling it releases causally initiate graft-directed humoral alloimmunity through the CXCL13/CXCR5 axis, and identify the innate pathways that license this axis. Concretely: (1) identify the cellular source(s) of CXCL13 induced after renal IRI and allogeneic kidney transplantation (candidate sources include, without limitation, infiltrating macrophages, stromal cells, follicular or peripheral T helper cells, and damaged tubular epithelial cells) and determine, for the innate pathways complement activation via C5a/C5aR1, TLR2/TLR4 signaling, and the cytokines IL-10 and IL-17, whether they are required for CXCL13 induction in vivo (determining the requirement status of any one of these pathway families suffices and the others are optional; other cytokines may be considered but are not required); and (2) by loss-of-function (pharmacologic blockade or genetic deletion of CXCL13 or CXCR5 in the recipient and/or graft), test whether the recruitment of CXCR5+ cells (B cells and other CXCR5+ infiltrates) into ischemic and allogeneically transplanted kidneys is a direct result of CXCL13 secretion rather than of ongoing renal inflammation independent of CXCL13, and whether this CXCL13-driven recruitment is necessary for de novo donor-specific antibody formation and antibody-mediated rejection after allogeneic kidney transplantation, or demonstrate instead that it is an epiphenomenon of injury-driven inflammation that can be disrupted without altering the alloimmune outcome. The chain of interest is graft ischemia → innate danger sensing (C5a/C5aR1, TLR2/4, cytokines) → CXCL13 production by a defined source → CXCR5+ cell recruitment (B cells and other CXCR5+ infiltrates) → graft-directed humoral alloimmunity, in a defined (pre)clinical kidney-transplant setting. Excluding a link requires interventions of verified efficacy (confirmed target engagement or genetic deletion, accounting for pathway redundancy where relevant) and endpoints appropriate to the link being adjudicated, of adequate power and assay specificity (humoral endpoints for the alloimmunity link; CXCL13 induction or CXCR5+ cell recruitment for upstream links). Establishing or excluding any one link at this standard counts as a solution, and adjudicating every link is not required. A solution may be presented either as an executed determination or as a loss-of-function program with pre-specified interventions and predicted outcomes.

References

  1. Kreimann K, Jang M-S, Rong S, Greite R, von Vietinghoff S, Schmitt R, Bräsen JH, Schiffer L, Gerstenberg J, Vijayan V, Dittrich-Breiholz O, Wang L, Karsten CM, Gwinner W, Haller H, Immenschuh S, Gueler F. 'Ischemia Reperfusion Injury Triggers CXCL13 Release and B-Cell Recruitment After Allogenic Kidney Transplantation.' Frontiers in Immunology 11:1204 (2020). DOI:10.3389/fimmu.2020.01204, https://doi.org/10.3389/fimmu.2020.01204
  2. Ochando J, Ordikhani F, Boros P, Jordan S. 'The innate immune response to allotransplants: mechanisms and therapeutic potentials.' Cellular & Molecular Immunology 16:350-356 (2019). DOI:10.1038/s41423-019-0216-2, https://doi.org/10.1038/s41423-019-0216-2
  3. Praska CE, Tamburrini R, Danobeitia JS. 'Innate immune modulation in transplantation: mechanisms, challenges, and opportunities.' Frontiers in Transplantation 2:1277669 (2023). DOI:10.3389/frtra.2023.1277669, https://doi.org/10.3389/frtra.2023.1277669
  4. Dery KJ, Yao S, Cheng B, Kupiec-Weglinski JW. 'New therapeutic concepts against ischemia-reperfusion injury in organ transplantation.' Expert Review of Clinical Immunology 19:1205-1224 (2023). DOI:10.1080/1744666X.2023.2240516, https://doi.org/10.1080/1744666X.2023.2240516
  5. Fan H, Liu J, Sun J, Feng G, Li J. 'Advances in the study of B cells in renal ischemia-reperfusion injury.' Frontiers in Immunology 14:1216094 (2023). DOI:10.3389/fimmu.2023.1216094, https://doi.org/10.3389/fimmu.2023.1216094
  6. Crichton ES, Zeng S, La Muraglia GM, Badell IR. 'CXCL13 Is an Indicator of Germinal Center Activity and Alloantibody Formation Following Transplantation.' Transplantation Direct 7:e785 (2021). DOI:10.1097/TXD.0000000000001247, https://doi.org/10.1097/TXD.0000000000001247
  7. Troise D, Infante B, Mercuri S, Lindholm B, Kublickiene K, Stallone G. 'Exploring the Immunological Landscape of Ischemia/Reperfusion Injury and Graft Rejection in Kidney Transplantation: Shared Mechanisms and Insights.' Cells 14:1443 (2025). DOI:10.3390/cells14181443, https://doi.org/10.3390/cells14181443
  8. Vázquez-Toledo MA, Guzmán-Martín CA, Juarez-Vicuña Y, Zepeda-Quiroz I, Flores-Gama C, Sánchez-Muñoz F. 'Is CXCL13 a key player of antibody-mediated rejection in kidney transplantation? A hypothesis based on its role in modulating the humoral response.' Medical Hypotheses 206:111842 (2026). DOI:10.1016/j.mehy.2025.111842, https://doi.org/10.1016/j.mehy.2025.111842
  9. Toyama C, Thomson AW. 'Innovative approaches targeting innate immune cells to promote organ transplant tolerance.' Frontiers in Transplantation 5:1776806 (2026). DOI:10.3389/frtra.2026.1776806, https://doi.org/10.3389/frtra.2026.1776806